Finance News – Weight Loss Drug
What is your interest today?
Bitcoin
Crypto
Btc
Stocks
Ceo
Investors
Shares
Tariffs
Stock
Stock Market
Crypto Assets
Cryptocurrency
Ethereum
Price
Markets
Xrp
Stablecoin
Etf
Investment
Bse
Blockchain
Ipo
Sec
Eth
Index
Solana
Trade
Inflation
Earnings
Interest Rates
Coinbase
Revenue
Token
Sensex
Wall Street
Nasdaq
China
Federal Reserve
Nse
Treasury
Traders
Bse Sensex
Gold
Sp 500
Nifty
Tesla
Economy
Profit
Usd
Investor
Us States
Presidential Candidate
Liquidity Venues
Ptg
Alk
Xivopower
Bakeries
Supreme Leader
Institutional Sales
Retail Customers
= 1024) { setSearchBy('title'); suggestionOpen = true; fetch() }"
@input.debounce.300ms="window.innerWidth >= 1024 && fetch()"
@keydown.enter.prevent="window.innerWidth >= 1024 && submitSearch()"
placeholder="Search finance news…"
class="flex-grow bg-transparent border-0 focus:ring-0 px-4 py-2 placeholder-gray-500 dark:placeholder-gray-400 text-gray-900 dark:text-gray-100 mr-2"
/>
Filter by:
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
Quartz • May 30, 2025
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Despite its initial leadership in the growing weight loss medication sector, Novo Nordisk has recently experienced a decline in market share compared to Eli Lilly, affecting its fi...
Read Full Article →
CNBC Business • May 19, 2025
Novo Nordisk is betting on a CEO shakeup to regain its weight loss drug edge over Eli Lilly
Novo Nordisk’s leadership change aims to strengthen its position in the weight loss market, improve competitive standing against Eli Lilly, and address upcoming industry challenges...
Read Full Article →